Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

(2021) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

(2020) Kenneth Cusi   DIABETES CARE

Therapeutic landscape for NAFLD in 2020

(2020) Brent A. Neuschwander-Tetri   GASTROENTEROLOGY

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

(2020) F. Anthony Romero et al.   JOURNAL OF MEDICINAL CHEMISTRY

Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis

(2020) Maya Balakrishnan et al.   Clinical Gastroenterology and Hepatology

Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

(2020) Jonathan G. Stine et al.   Clinical Gastroenterology and Hepatology

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes

(2020) Zobair M. Younossi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

AMP-activated protein kinase: the current landscape for drug development

(2019) Gregory R. Steinberg et al.   NATURE REVIEWS DRUG DISCOVERY

Sex Differences in NAFLD : State of the Art and Identification of Research Gaps

(2019) Amedeo Lonardo et al.   HEPATOLOGY

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States

(2019) Zobair M. Younossi et al.   DIABETES CARE

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

(2019) Fernando Bril et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

(2019) Gordon I. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Promise and challenges for direct small molecule AMPK activators

(2018) Séverine Olivier et al.   BIOCHEMICAL PHARMACOLOGY

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

(2018) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

AMPK: guardian of metabolism and mitochondrial homeostasis

(2017) Sébastien Herzig et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Treatment of nonalcoholic fatty liver disease: role of AMPK

(2016) Brennan K. Smith et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Current efforts and trends in the treatment of NASH

(2015) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

(2014) Anila K. Madiraju et al.   NATURE

Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging

(2013) Xiaodong Zhong et al.   MAGNETIC RESONANCE IN MEDICINE

Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle

(2011) I. Chopra et al.   DIABETOLOGIA

Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans

(2010) Marie-Soleil Gauthier et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

AMPK inhibition in health and disease

(2010) Benoit Viollet et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

An energetic tale of AMPK-independent effects of metformin

(2010) Russell A. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

(2009) P. Aschner et al.   DIABETES OBESITY & METABOLISM

Visceral fat: A key mediator of steatohepatitis in metabolic liver disease

(2008) David van der Poorten et al.   HEPATOLOGY